Satavaptan

Satavaptan

Satavaptan (INN; codenamed SR121463, planned tradename Aquilda) is a vasopressin-2 receptor antagonist[1] undergoing research for the treatment of hyponatremia. It is also being studied for the treatment of ascites.[2]

It was developed by Sanofi-Aventis. As of 2008, it is under regulatory review in the European Union.

References